神州數碼(000034.SZ):近期已發佈人工智能相關產品“神州問學”
格隆匯11月3日丨神州數碼(000034.SZ)於2023年10月31日接受特定對象調研,就“公司數雲融合實驗室產品開發進展及未來收益情況?”,公司回覆稱,公司的數雲融合實驗室聚焦雲原生產品、多雲管理平台以及雲原生數據平台等產品的開發,為公司數雲融合戰略落地及業務轉型提供有力的支撐。我們將通過持續的研發投入,提升公司的雲原生和數據原生方面的競爭力。公司近期已發佈人工智能相關產品“神州問學”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.